Literature DB >> 18201827

Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns.

Yuesheng Huang1, Kang Xie, Jiaping Zhang, Yongming Dang, Zhang Qiong.   

Abstract

OBJECTIVE: To investigate the preventive effect of ulinastatin on shock in the heart after burn.
METHODS: In an open prospective clinical study 34 adults with burns >50% total body surface area were randomly divided into control (B) and ulinastatin-treated (U) groups. All underwent routine treatment, and group U received 100,000U ulinastatin intravenously three times a day for 1 week. In an animal experiment, 72 healthy rats underwent equivalent burn, similar division into groups B and U, and resuscitation according to Parkland's formula. Rats in group U received ulinastatin (40,000U/kg) immediately after burn. Myocardial pathomorphology, plasma cTnI, CK-MB and PMNE, myocardial MDA, TNF-alpha, IL-10 and caspase-3 activity and cardiocyte apoptosis were determined.
RESULTS: Plasma cTnI, CK-MB, and PMNE were higher in clinical group B than group U. In the animal experiment, plasma cTnI, CK-MB, myocardial MDA, TNF-alpha, IL-10 and caspase-3 activity, and apoptotic index and myocardial pathomorphological changes were significantly less in group U than in group B, save IL-10.
CONCLUSION: The clinical and experimental data showed that ulinastatin relieved myocardial damage from severe burn. The mechanism might involve modulation of the anti- and pro-inflammatory balance and lipid peroxidation, and decreased myocardiocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201827     DOI: 10.1016/j.burns.2007.08.024

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  8 in total

1.  Protective effects of ulinastatin on acute liver failure induced by lipopolysaccharide/D-galactosamine.

Authors:  Jie Lu; Yong-Ping Chen; Rong Wan; Chuan-Yong Guo; Xing-Peng Wang
Journal:  Dig Dis Sci       Date:  2011-10-15       Impact factor: 3.199

2.  Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19.

Authors:  Ashish Jain; Rajeev Kasliwal; Srishti Suresh Jain; Rohit Jain; Divyansh Gupta; Priyamvada Gupta; Anand Jain; Rohan Tambi; Puneet Panwar; Munesh Meena; Ravi Jain
Journal:  Indian J Crit Care Med       Date:  2022-06

3.  Prospective experimental studies on the renal protective effect of ulinastatin after paraquat poisoning.

Authors:  Zhi-Jian Zhang; Li-Bo Peng; Ya-Juan Luo; Cong-Yang Zhou
Journal:  World J Emerg Med       Date:  2012

4.  Ulinastatin attenuates protamine-induced cardiotoxicity in rats by inhibiting tumor necrosis factor alpha.

Authors:  Hisashi Fukushima; Takeshi Oguchi; Hiroaki Sato; Yosuke Nakadate; Tamaki Sato; Keisuke Omiya; Akiko Kawakami; Toru Matsuoka; Takashi Matsukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-08       Impact factor: 3.000

5.  Ulinastatin did not reduce mortality in elderly multiple organ failure patients: a retrospective observational study in a single center ICU.

Authors:  Masatoshi Uchida; Toshikazu Abe; Kazuyuki Ono; Nanako Tamiya
Journal:  Acute Med Surg       Date:  2017-08-18

6.  Ulinastatin suppresses burn-induced lipid peroxidation and reduces fluid requirements in a Swine model.

Authors:  Hong-Min Luo; Ming-Hua Du; Zhi-Long Lin; Quan Hu; Lin Zhang; Li Ma; Huan Wang; Yu Wen; Yi Lv; Hong-Yuan Lin; Yu-Li Pi; Sen Hu; Zhi-Yong Sheng
Journal:  Oxid Med Cell Longev       Date:  2013-04-24       Impact factor: 6.543

Review 7.  Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Qiu-Lan He; Fei Zhong; Fang Ye; Ming Wei; Wei-Feng Liu; Mei-Na Li; Qiao-Bo Li; Wen-Qi Huang; Lai-Bao Sun; Hai-Hua Shu
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

8.  Cryptdin-2 predicts intestinal injury during heatstroke in mice.

Authors:  Jingjing Ji; Zhengtao Gu; Hui Li; Lei Su; Zhifeng Liu
Journal:  Int J Mol Med       Date:  2017-11-01       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.